Bokf Na Reduces Holdings in West Pharmaceutical Services, Inc. $WST

Bokf Na decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 71.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 805 shares of the medical instruments supplier’s stock after selling 2,046 shares during the period. Bokf Na’s holdings in West Pharmaceutical Services were worth $221,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in WST. Empowered Funds LLC increased its stake in West Pharmaceutical Services by 16.1% during the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 224 shares during the period. Intech Investment Management LLC increased its stake in West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after buying an additional 1,307 shares during the period. Acadian Asset Management LLC increased its stake in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after buying an additional 157 shares during the period. EverSource Wealth Advisors LLC increased its stake in West Pharmaceutical Services by 78.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 197 shares during the period. Finally, First Trust Advisors LP increased its stake in West Pharmaceutical Services by 168.4% during the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after buying an additional 29,067 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 0.1%

NYSE:WST opened at $326.12 on Monday. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $261.47 and its two-hundred day moving average is $264.28. West Pharmaceutical Services, Inc. has a 52 week low of $202.79 and a 52 week high of $328.44. The company has a market cap of $23.04 billion, a PE ratio of 43.60, a P/E/G ratio of 2.72 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. During the same quarter last year, the business posted $1.45 EPS. West Pharmaceutical Services’s quarterly revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts predict that West Pharmaceutical Services, Inc. will post 8.61 EPS for the current year.

West Pharmaceutical Services announced that its Board of Directors has authorized a share repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th were given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is currently 11.76%.

Insider Transactions at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This represents a 37.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on WST. Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Jefferies Financial Group reissued a “buy” rating and issued a $295.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. UBS Group reissued a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Finally, Morgan Stanley set a $315.00 target price on shares of West Pharmaceutical Services in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $322.89.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.